Dr. Michael Martin is President of Takeda Ventures, Inc. (TVI) and he is based in San Diego, CA. His professional background includes venture capital, pharma business development and broad R&D experiences with an integral role in the discovery and development of 17 innovative investigational drugs and 2 commercial products. Prior to joining TVI, Dr. Martin was most recently a member of Global Licensing and Business Development at Takeda, heading efforts for sourcing and transacting technologies and early stage pipeline programs. Dr. Martin has held executive and scientific roles with Intellikine (acquired by Takeda), TargeGen (acquired by Sanofi-Aventis), Arena Pharmaceuticals and Monsanto Corporation.
Dr. Martin is currently a director at ArmaGen, Avidity Biosciences, BioMotiv, Bioniz, Cortexyme, FutuRx, Hookipa Biotech, OrphoMed, Univercells and an advisory to Arix Biosciences, Atlas Ventures and UK Dementia Discovery Fund. Dr. Martin earned his doctorate in Medicinal Chemistry from the University of Illinois and holds a M.S. degree in analytical chemistry and B.S. degrees in Chemistry and Mathematics.